Format

Send to

Choose Destination
Mol Genet Metab. 2018 Mar;123(3):326-330. doi: 10.1016/j.ymgme.2017.09.003. Epub 2017 Sep 11.

Sleep and quality of life of patients with glycogen storage disease on standard and modified uncooked cornstarch.

Author information

1
Department of Pediatrics, Division of Pediatric Endocrinology, Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada.
2
Department of Pediatrics, Division of Pediatric Endocrinology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
3
Department of Pediatrics, Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada.
4
Research Institute - McGill University Health Centre, Montreal, Quebec, Canada.
5
Department of Medicine, Division of Hepatology, Hôpital St-Luc du Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, Quebec, Canada.
6
Department of Pediatrics, Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada. Electronic address: evelyn.constantin@mcgill.ca.
7
Department of Pediatrics, Division of Pediatric Endocrinology, Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada. Electronic address: john.mitchell@muhc.mcgill.ca.

Abstract

BACKGROUND:

Glycemic control in hepatic glycogen storage diseases (GSDs) relies on specific nutritional recommendations, including strict avoidance of a fasting period. Uncooked cornstarch (UCCS) is an important therapeutic component. A new modified UCCS, Glycosade™, was created with the objective of prolonging euglycemia. We aimed to determine the length of euglycemia on Glycosade™ using a continuous glucose monitor (CGM) and to evaluate whether longer euglycemia and thus less nighttime interruptions would improve sleep and quality of life (QoL) after the introduction of the modified cornstarch.

METHODS:

We conducted a prospective cohort study to assess quality and quantity of sleep and quality of life (QoL) in patients with GSDs on standard UCCS and after the introduction of Glycosade™. Sleep and QoL evaluation was done for patients using validated questionnaires, a standardized sleep diary and actigraphy. Length of fast and glucose variability were determined with CGM.

RESULTS:

Nine adults with GSD Ia took part in the study. Glycosade™ introduction was done under close supervision during a hospital admission. Comparison of sleep in 9 patients showed sleep disturbances on standard UCCS that were improved with Glycosade™. QoL was normal both pre and post Glycosade™. The CGM confirmed maintenance of a longer fasting period with Glycosade™ at home.

CONCLUSION:

Glycosade™ represents an alternative option for GSD patients. We showed possible benefits in terms of sleep quality. We also confirmed the longer length of fast on Glycosade™.

SYNOPSIS:

A new modified form of uncooked starch for patients with glycogen storage disease represents an alternative option as it showed a longer length of fast and improvements in sleep quality.

KEYWORDS:

Glycogen storage disease; Quality of life; Sleep; Uncooked cornstarch

PMID:
29223626
DOI:
10.1016/j.ymgme.2017.09.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center